Thromboembolic Disorders

HCV Treatment Linked to Reduced Risk of Incident CVD Events

By November 15, 2018

ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) was utilized to identify all patients who received HCV treatment for at least 7 weeks as well as a propensity-score matched group who did not receive treatment.

Sudden Cardiac Death Rates Up in Black Adults Versus White Adults

November 14, 2018

Risk still up after adjustment for sociodemographics, comorbidity, behavioral measures of health

Can Omega-3 Help Reduce MACE in High Risk Patients With Hypertriglyceridemia?

November 13, 2018

In high-risk patients with mild hypertriglyceridemia, omega-3 fatty acids improved triglyceride levels and reduced major adverse cardiovascular events, according to a new meta-analysis.

Calcium Channel Blockers May Reduce Peripheral Arterial Disease Risk

November 13, 2018

Meta-analysis suggests that calcium channel blockers can be effective in preventing peripheral arterial disease in patients with hypertension.

Difference in CV Outcomes Explored With Dapagliflozin, Vildagliptin

November 09, 2018

The dapagliflozin treatment arm experienced significant body weight reductions, lower body mass index scores, lower systolic blood pressure, and an increase in levels of hemoglobin (P<.05).

After 2007 Heart Association Recs, Increase Seen in Infective Endocarditis

November 07, 2018

Following the 2007 American Heart Association (AHA) update of recommendations for antibiotic prophylaxis (AP) to prevent infective endocarditis (IE), there has been a decrease in AP and an increase in IE incidence for high-risk individuals.

FDA: Class I Recall of Test Strips Due to Inaccurate INR Results

By November 02, 2018

Over 1.1 million packages of test strips distributed from January 12, 2018 to October 29, 2018 are being recalled.

Invokana Approved to Reduce Risk of Major Adverse Cardiovascular Events

By October 30, 2018

The effect of Invokana on CV risk was evaluated in the CANVAS (CANagliflozin cardioVascular Assessment Study) Program in >10,000 adults with T2D who had established CV disease or were at risk for CV disease with ≥2 risk factors.

Cardiac Stem Cell Trial Halted Due to Concerns About Fake Data

October 30, 2018

The clinical trial is based on research from a number of laboratories, including that of Harvard-affiliated Brigham and Women's Hospital researcher Piero Anversa, MD.

Saxenda Labeling Updated With Cardiovascular Safety Data

By October 23, 2018

The randomized, double-blind, placebo-controlled, parallel-group study (N=9340) evaluated the time from randomization to first occurrence of major adverse CV events (MACE) (non-fatal heart attack, non-fatal stroke, CV death) in patients treated with liraglutide 1.8mg once daily or placebo.

Aspirin, Anticoagulants Similarly Prevent VTE After TKA

October 19, 2018

The researchers found that VTE events occurred in 1.38% of patients, including 4.79% of those who received no pharmacologic prophylaxis, 1.16% treated with aspirin alone, 1.42% of those treated with anticoagulation alone, and 1.31% prescribed both aspirin and anticoagulation.

Xarelto Approved to Reduce Risk of Major Cardiovascular Events in Patients With CAD, PAD

By October 12, 2018

The FDA approval was supported by data from the Phase 3 COMPASS trial (N=27,395) which evaluated Xarelto with or without aspirin for the long-term prevention of major adverse CV events (including MI, stroke, CV death) in patients with chronic CAD or PAD.

Empagliflozin Impact on Life Expectancy Examined in T2DM Patients With CVD

By October 10, 2018

For this analysis, the authors used follow-up data from all 7020 patients included in the EMPA-REG OUTCOME trial to estimate the effect of empagliflozin on all-cause mortality vs placebo over the duration of a patient's lifetime.

Statins May Decrease the Risk for Active Tuberculosis

October 09, 2018

The use of statins may decrease the risk for active tuberculosis.

Is a Physician Liable When a Patient Fails to Follow Discharge Instructions?

By October 02, 2018

Dr C was determined to fight this case, and his defense attorney was supportive after looking at the detailed notes and documented calls to the patient which were never returned.

Patient Develops Acquired Hemophilia After Treatment With Levofloxacin

By September 27, 2018

Although discontinuation of the medication resolved the patient's symptoms initially, spontaneous bruising recurred and progressed over several weeks, prompting the patient to seek medical attention for persistent bruising in her upper extremities.

Rivaroxaban does not decrease rates of venous thromboembolism complications

September 26, 2018

At a median follow-up of 3.3 years, rates of symptomatic venous thromboembolism or death due to thromboembolism were similar for medically ill patients treated with rivaroxaban or placebo for 45 days following hospital discharge.

FDA Approves Eluvia Drug-Eluting Stent for Peripheral Artery Disease Treatment

By September 24, 2018

The Eluvia stent is designed to release paclitaxel for a 1-year time frame to prevent tissue regrowth that might otherwise block the stented artery.

No Clear Benefit for Rivaroxaban After Hospital Discharge

September 20, 2018

The researchers found that a composite outcome of symptomatic venous thromboembolism or death due to venous thromboembolism occurred in 0.83% of patients in the rivaroxaban group and in 1.10% in the placebo group (hazard ratio, 0.76; 95% confidence interval, 0.52 to 1.09; P=0.14).

FDA: Final Guidance on Heparin-Containing Devices, Combo Products

By September 19, 2018

The intent of the document is to help reduce heparin product overdose errors caused by misinterpretation of the drug strength displayed in the labeling.

FDA Approves New Stent System to Treat Acute Coronary Artery Perforations

By September 17, 2018

The Agency reviewed real-world data from 80 patients who received the PK Papyrus Stents, finding that the stents were delivered successfully to the perforation site in 95% of patients with successful seals seen in 73 patients 91.3% of patients.

FDA to Review Praluent as Potential Treatment to Reduce Risk of MACE

By September 12, 2018

The sBLA is supported by data from the Phase 3 ODYSSEY OUTCOMES trial which included 18,924 patients who had experienced an acute coronary syndrome (ACS) in the previous 12 months.

Cardiovascular Health Risks Identified With Diclofenac Use

By September 07, 2018

To investigate the cardiovascular risks associated with diclofenac, researchers conducted a series of cohort studies mimicking the design criteria of a clinical trial.

Anti-Nicotine Monoclonal Antibody Gets Orphan Drug Status for Buerger's Disease

By September 05, 2018

Buerger's disease is a nonatherosclerotic, segmental inflammatory disorder that affects small and medium vessels of the upper and lower extremities and is strongly associated with tobacco exposure.

Transcranial direct current stimulation linked to improved naming post-stroke

August 30, 2018

In this randomized trial of patients with aphasia, use of anodal transcranial direct current stimulation (A-tDCS) demonstrated improved object naming compared to sham procedure.

VKA vs Non-VKA Oral Anticoagulants: Mortality Rates Compared in AF

By August 29, 2018

The new analysis included 19,134 of these patients and showed that there were 19% fewer deaths in patients initiated on NOACs compared to VKAs at the time of AF diagnosis.

Does Aspirin Cut the Risk of Initial Vascular Events in Patients at Moderate CVD Risk?

By August 28, 2018

For this double-blind, placebo-controlled study, researchers selected male patients ≥55 years and female patients ≥60 years with average cardiovascular risk and assigned them to enteric-coated aspirin 100mg (N=6270) or placebo (N=6276) once daily; the median follow-up time was 60 months.

Lorcaserin Facilitates Weight Loss Without Increasing Risk of Major CV Events

By August 27, 2018

In the CAMELLIA-TIMI 61 study, 12,000 overweight or obese patients with atherosclerotic cardiovascular disease or multiple cardiovascular risk factors were randomized to receive either lorcaserin 10mg twice daily or placebo.

Breastfeeding Linked to Lower Risk of Stroke Post-Menopause

August 24, 2018

Compared with women who had never breastfed, those who reported ever breastfeeding had a significantly lower risk of stroke after adjustment for non-modifiable potential confounders (adjusted hazard ratio, 0.77).

Xenon Gas for Inhalation Therapy Gets Fast-Tracked for Post-Cardiac Arrest Syndrome

By August 23, 2018

Treatment with xenon may improve functional outcomes and reduce mortality in cardiac arrest survivors.